Saturday, August 30, 2014 12:35:26 AM
What utter contrived hogwash,..... Nothing but unsupported hyperbole.
And it won't be sent to the SEC - because fact is - there is nothing illegal in it or actionable in it, or even particularly calling into question of the credibility of Dr. Seymour in that set of short statements.
The message states facts - if a bit done up like sound bites.
People were - and still are - paying too much attention to the stock price on a daily basis. If you are playing the 'long' game here and not trading in and out - the daily fluctiations ARE meaningless.
People who obsess about the daily fluctions who are not trading in and out will make themselves crazy.
The science is moving along - if slower than just about any of us would like. And it is the science that will drive the success or failure of NNVC.
If you do have confidence in the company and where it is going - then buying more when the prices drop makes complete sense to lower your cost average. I've not bought any additional shares since before the R/S - but I've 'bought more' when the 'prices drop' with some regularity over the years here that I have been accumulating.
The message being parsed here is a bit "Rah Rah!", but it is actually on the face of it a series of perfectly reasonable statements - if a touch less than perfectly professionally put together.
I can tell you - the SEC won't do anything about this because there is nothing in it to be 'done' as actionable. Nothing even close.
Recent NNVC News
- NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/01/2023 08:46:45 PM
- Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs • InvestorsHub NewsWire • 07/06/2023 03:16:37 PM
FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM